| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Silver NanoParticles (AgNPs) Summary: 1.Smaller sizes are generally more bioactive due to increased surface area and enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect. 2.Two relevant forms: particulate silver (AgNPs) and ionic silver (Ag⁺). There is debate regarding oral use, as Ag⁺ can precipitate as AgCl in gastric acid, reducing bioavailability; AgNPs may partially avoid this via particulate uptake and intracellular Ag⁺ release. Gastric pH may influence this equilibrium. 3. Dose example 80kg person: 1.12-2mg/day, which can be calculated based on ppm and volume taken (see below) target < 10ppm and 120mL per day (30ppm and 1L per day caused argyria 30mg/day ) (Case Report: 9‐15 ppm@120mL, i.e. 1.1mg/L to 1.8mg/L per day) Likely 10ppm --> 10mg/L, hence if take 100mL, then 1mg/day? (for Cancer) The current Rfd for oral silver exposure is 5 ug/kg/d with a critical dose estimated at 14 ug/kg/d for the average person. Seems like the Cancer target range is 14ug/kg/day to 25ug/kg/day. 80Kg example: 1.12mg to 2mg “1.4µg/kg body weight. If I would have 70kg, I would want to use 100µg/day. However, for fighting active disease, I would tend to explore higher daily dose, as I think this may be too low.” These values reflect experimental or anecdotal contexts and are not established safe or therapeutic doses. 4. Antioxidants such as NAC can counteract AgNP cytotoxicity by restoring glutathione pools and suppressing ROS-mediated mitochondrial damage. 5. In vitro studies commonly show ROS elevation in both cancer and normal cells; however, in vivo, superior antioxidant, NRF2, and repair capacity in normal tissues may confer selectivity. 6. Pathways/mechanisms of action/: -” intracellular ROS was increased...reduction in levels of glutathione (GSH)” - Normal-cell selectivity is partly mediated by NRF2-dependent antioxidant and detoxification responses. - AgNPs impair mitochondrial electron transport, increasing electron leak and amplifying ROS upstream of ΔΨm collapse. -AgNPs inhibit VEGF-driven endothelial signaling and permeability (anti-angiogenic effect) -”upregulation of proapoptotic genes (p53, p21, Bax, and caspases) and downregulation of antiapoptotic genes (Bcl-2)” -” upregulation of AMPK and downregulation of mTOR, MMP-9, BCL-2, and α-SMA” -”p53 is a key player...proapoptotic genes p53 and Bax were significantly increased... noticeable reduction in Bcl-2 transcript levels” -” p53 participates directly in the intrinsic apoptosis pathway by regulating the mitochondrial outer membrane permeabilization” - “Proapoptotic markers (BAX/BCL-XL, cleaved poly(ADP-ribose) polymerase, p53, p21, and caspases 3, 8 and 9) increased.” -”The antiapoptotic markers, AKT and NF-kB, decreased in AgNP-treated cells.” Chronic accumulation and long-term systemic effects remain insufficiently characterized. Silver NanoParticles and Magnetic Fields Summary: 1. “exposure to PMF increased the ability of AgNPs uptake” 2. 6x improvement from AgNPs alone could glucose capping of SilverNPs work as trojan horse? Sodium selenite might protect against toxicity of AgNPs in normal cells. -uncoated AgNPs can degrade the gut microbiome. PVP, citrate, green-synthesized, chitosan coating, may reduce the effect. Similar oxidative considerations may apply to selenium compounds, though mechanisms differ. co-ingestion with food (higher pH) favors reduction and lower Ag+ levels. -action mechanisms of AgNPs: the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure. AgNP anticancer effects come from three overlapping mechanisms: -Nanoparticle–cell interaction (uptake, membrane effects) -Intracellular ROS generation -Controlled Ag⁺ release inside cancer cells Comparison adding Citrate Capping | Property | Uncapped AgNPs | Citrate-capped AgNPs | | --------------------- | -------------- | -------------------- | | Stability | Poor | Excellent | | Free Ag⁺ | High | Low | | Normal cell toxicity | Higher | Lower | | Cancer selectivity | Lower | **Higher** | | Mechanism specificity | Crude | **Targeted** | | Storage behavior | Degrades | Stable |
|
| Source: HalifaxProj(prevent) |
| Type: |
| DNA damage plays a crucial role in the development of cancer. The integrity of DNA is essential for the proper functioning of cells, and when DNA is damaged, it can lead to mutations that may contribute to cancer progression. |
| 4564- | AgNPs, | GoldNP, | Cu, | Chemo, | PDT | Cytotoxicity and targeted drug delivery of green synthesized metallic nanoparticles against oral Cancer: A review |
| - | Review, | Var, | NA |
| 4561- | AgNPs, | VitC, | Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | HEK293 |
| 5978- | AgNPs, | Biological synthesis of silver nanoparticles and their medical applications |
| - | Review, | Var, | NA |
| 5236- | AgNPs, | Adaptive regulations of Nrf2 alleviates silver nanoparticles-induced oxidative stress-related liver cells injury |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | L02 |
| 5144- | AgNPs, | Differential effects of silver nanoparticles on DNA damage and DNA repair gene expression in Ogg1-deficient and wild type mice |
| - | in-vivo, | Nor, | NA |
| 4403- | AgNPs, | Silver Nanoparticles Decorated UiO-66-NH2 Metal-Organic Framework for Combination Therapy in Cancer Treatment |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | GL26 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | CRC, | RKO |
| 4401- | AgNPs, | Rad, | Metformin-loaded chitosan nanoparticles augment silver nanoparticle-induced radiosensitization in breast cancer cells during radiation therapy |
| - | in-vitro, | BC, | NA |
| 4400- | AgNPs, | Rad, | Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | BC, | MDA-MB-231 |
| 4399- | AgNPs, | Chit, | Silver nanoparticles impregnated alginate-chitosan-blended nanocarrier induces apoptosis in human glioblastoma cells |
| - | in-vitro, | GBM, | U87MG |
| 4542- | AgNPs, | Silver Nanoparticles (AgNPs): Comprehensive Insights into Bio/Synthesis, Key Influencing Factors, Multifaceted Applications, and Toxicity─A 2024 Update |
| - | Review, | NA, | NA |
| 4549- | AgNPs, | Silver nanoparticles: Synthesis, medical applications and biosafety |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA |
| 4438- | AgNPs, | ART/DHA, | Biogenic synthesis of AgNPs using Artemisia oliveriana extract and their biological activities for an effective treatment of lung cancer |
| - | in-vitro, | Lung, | A549 |
| 4428- | AgNPs, | p38 MAPK Activation, DNA Damage, Cell Cycle Arrest and Apoptosis As Mechanisms of Toxicity of Silver Nanoparticles in Jurkat T Cells |
| - | in-vitro, | AML, | Jurkat |
| 2288- | AgNPs, | Silver Nanoparticle-Mediated Cellular Responses in Various Cell Lines: An in Vitro Model |
| - | Review, | Var, | NA |
| 400- | AgNPs, | MF, | Polyvinyl Alcohol Capped Silver Nanostructures for Fortified Apoptotic Potential Against Human Laryngeal Carcinoma Cells Hep-2 Using Extremely-Low Frequency Electromagnetic Field |
| - | in-vitro, | Laryn, | HEp2 |
| 4362- | AgNPs, | Enhancing Colorectal Cancer Radiation Therapy Efficacy using Silver Nanoprisms Decorated with Graphene as Radiosensitizers |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vivo, | NA, | NA |
| 4371- | AgNPs, | Effects of Green Silver Nanoparticles on Apoptosis and Oxidative Stress in Normal and Cancerous Human Hepatic Cells in vitro |
| - | in-vitro, | Liver, | HUH7 |
| 334- | AgNPs, | Silver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53 |
| - | in-vitro, | Colon, | HCT116 |
| 342- | AgNPs, | Silver nanoparticles; a new hope in cancer therapy? |
| - | Review, | NA, | NA |
| 388- | AgNPs, | Apoptotic efficacy of multifaceted biosynthesized silver nanoparticles on human adenocarcinoma cells |
| - | in-vitro, | BC, | MCF-7 |
| 322- | AgNPs, | Cisplatin, | Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
| 327- | AgNPs, | MS-275, | Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells |
| - | in-vitro, | Lung, | A549 |
| 374- | AgNPs, | Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 376- | AgNPs, | Antitumor activity of colloidal silver on MCF-7 human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 384- | AgNPs, | Dual functions of silver nanoparticles in F9 teratocarcinoma stem cells, a suitable model for evaluating cytotoxicity- and differentiation-mediated cancer therapy |
| - | in-vitro, | Testi, | F9 |
| 386- | AgNPs, | Tam, | Synergistic anticancer effects and reduced genotoxicity of silver nanoparticles and tamoxifen in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 369- | AgNPs, | Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis |
| - | in-vitro, | Liver, | NA |
| 360- | AgNPs, | Moringa, | Cytotoxic and Genotoxic Evaluation of Biosynthesized Silver Nanoparticles Using Moringa oleifera on MCF-7 and HUVEC Cell Lines |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | HUVECs |
| 362- | AgNPs, | Comparative and Mechanistic Study on the Anticancer Activity of Quinacrine-Based Silver and Gold Hybrid Nanoparticles in Head and Neck Cancer |
| - | vitro+vivo, | SCC, | SCC9 |
| 355- | AgNPs, | Cytotoxicity and Genotoxicity of Biogenic Silver Nanoparticles in A549 and BEAS-2B Cell Lines |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | NA, | BEAS-2B |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:153 Target#:82 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid